161957-53-5

Basic information

• Product Name: Silane, (3-bromo-2-fluorophenyl)trimethyl-
• CAS NO: 161957-53-5
• Molecular Formula: C9H12BrFSi
• Molecular Weight: 247.182
• Mol File: 161957-53-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Silane, (3-bromo-2-fluorophenyl)trimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Silane, (3-bromo-2-fluorophenyl)trimethyl-(161957-53-5)
• EPA Substance Registry System: Silane, (3-bromo-2-fluorophenyl)trimethyl-(161957-53-5)

Safety Data

• Hazardous Substances Data: 161957-53-5(Hazardous Substances Data)

Upstream product

• 75-77-4 chloro-trimethyl-silane 
• 1072-85-1 o-fluorobromobenzene 

Downstream Products

• 161957-61-5 1-(3-bromo-2-fluorophenyl)ethan-1-one 

Relevant articles and documents

Transition-Metal-Free Silylation of Unactivated C(sp2)-H Bonds withtert-Butyl-Substituted Silyldiazenes

Aromatic organosilanes bearing C(sp2)-Si bonds have found increasing applications across the chemical science, yet are mostly produced by atom-uneconomical stoichiometric procedures. Catalytic alternatives using hydrosilanes as silicon sources

Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.

2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.